[Therapeutic effect of hepatoprotectors in experimental Reye syndrome].
Maxar and legalon--hepatoprotectors containing polyphenols--exhibit a therapeutic effect with respect to the experimental Reye's syndrome induced in rats by intraperitoneal injections of 4-pentenoic acid. Maxar restores the activity of enzymes of the hepatic origin, normalizes the content of bilirubin, glucose, phenols, and malonic aldehyde in the blood serum, stimulates the production of ketone bodies and ammonia detoxication, and improves the histologic structures of liver and cortex. Legalon also decreases the structural-metabolic disorders accompanying the Reye's syndrome, but to as lower ewxtent.
Vengerovskiĭ
A I
AI
Pharmacology Department, Siberian Medical University, Tomsk, Russia.
Sukhodolo
I V
IV
Chuchalin
V S
VS
Arbuzov
A G
AG
Cherviakova
M B
MB
Mel'nik
Iu Iu
IuIu
Grishina
E I
EI
Fedoreev
S A
SA
Saratikov
A S
AS
D000818:Animals; D001921:Brain / Q000473:pathology; D005229:Fatty Acids, Monounsaturated; D007529:Isoflavones / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism / Q000473:pathology; D010936:Plant Extracts / Q000627:therapeutic use; D051381:Rats; D012202:Reye Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D012838:Silymarin / Q000627:therapeutic use*; D013267:Stilbenes / Q000627:therapeutic use*
D005229:Fatty Acids, Monounsaturated; D007529:Isoflavones; D010936:Plant Extracts; D012838:Silymarin; D013267:Stilbenes; C009785:4-pentenoic acid